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Irritable bowel syndrome (IBS) is characterized by recurrent abdominal discomfort, spontaneous pain, colorectal
hypersensitivity and bowel dysfunction. Patients with IBS also suffer from emotional anxiety and depression.
However, few animal studies have investigated IBS-induced spontaneous pain and behavioral anxiety. In this study, we
assessed spontaneous pain and anxiety behaviors in an adult mouse model of IBS induced by zymosan administration.
By using Fos protein as a marker, we found that sensory and emotion related brain regions were activated at day 7
after the treatment with zymosan; these regions include the prefrontal cortex, anterior cingulate cortex, insular cortex
and amygdala. Behaviorally, zymosan administration triggered spontaneous pain (decreased spontaneous activities in
the open field test) and increased anxiety-like behaviors in three different tests (the open field, elevated plus maze and
light/dark box tests). Intraperitoneal injection of NB001, an adenylyl cyclase 1 (AC1) inhibitor, reduced spontaneous pain
but had no significant effect on behavioral anxiety. In contrast, gabapentin reduced both spontaneous pain and
behavioral anxiety. These results indicate that NB001 and gabapentin may inhibit spontaneous pain and anxiety-like
behaviors through different mechanisms.
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Visceral pain occurs after mechanical or chemical stimula-
tion in and around the internal organs. This form of pain
is vague and poorly localized [1-4]. Typical phenotypes of
visceral pain include hyperalgesia, in which enhanced pain
responses are induced by weak noxious visceral stimuli,
and allodynia, in which innocuous visceral stimuli can
cause pain. In addition, spontaneous pain or discomfort
can frequently be observed [5]. Irritable bowel syndrome
(IBS), a major form of chronic visceral pain, is accompan-
ied by visceral hyperalgesia, abnormal bowel habits and
spontaneous pain or discomfort [6,7]. Recent studies
indicate that an enhanced primary sensory afferent derived
from the colorectum maintained IBS-related pain and* Correspondence: deptanat@fmmu.edu.cn; min.zhuo@utoronto.ca
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unless otherwise stated.associated colorectal hypersensitivity [7-9]. It is very
likely that enhanced sensory inputs into the central
nervous system may trigger long-term changes in brain
areas associated with emotional and cognitive processing.
Unsurprisingly, it has been reported that IBS is accompan-
ied by severe anxiety, stress and depression [10-15]. Most
of previous animal studies of IBS only focused on sensory
mechanisms; few examined behavioral and emotional
changes in IBS.
Cortical and subcortical areas, such as the prefrontal
cortex (PFC), anterior cingulate cortex (ACC), insular
cortex and amygdala, are important for processing pain,
discomfort and emotional responses [16-23]. Animal
and human brain imaging studies show that IBS affects
neuronal activities in these brain areas, specifically the
ACC [24-30]. In previous studies, we found that pain
and pain-related emotional changes triggered long-term
potentiation (LTP) of synaptic transmission in the ACC
[18,31,32]. Calcium-stimulated adenylyl cyclase subtype 1
(AC1) plays important roles in pain-related LTP in the
ACC as well as in injury-induced plastic changes [33-36].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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hibitor NB001 causes analgesic effects in mice with somatic
tissue injury, inflammation or muscle pain [37-39]. How-
ever, the possible effect of an AC1 inhibitor on IBS-induced
pain or anxiety has not been investigated.
In the present study, we began by labeling Fos protein,
a marker of neural activity, in mouse brains to detect the
activation of brain areas that are important for pain
processing as well as the processing of anxiety and fear.
Second, we wanted to establish behavioral measurement
of spontaneous pain, discomfort and behavioral anxiety
in adult mice with intra-colonic injection of zymosan,
a common animal model to mimic the clinical IBS
[40,41]. Finally, we evaluated the effects of the AC1 inhibi-
tor NB001 and gabapentin, a commonly used anticonvul-
sant and analgesic component in treating seizures and
somatic neuropathic pain [42-44], on spontaneous pain and
behavioral anxiety, as well as other behavioral responses.
Results
Zymosan increases the expression of Fos protein in the
central nervous system
First, we sought to determine whether IBS activates
sensory and emotion related brain areas. Neuronal Fos
protein expression is commonly used as a correlative
indicator of neuronal activity induced by somatic or
visceral noxious stimuli [20,45,46]. We performed Fos
immunohistochemical staining to determine whether
cortical and subcortical neurons are involved in zymosan-
induced colitis on day 7 after injections of zymosan. This
time point was chosen because our preliminary experi-
ments have indicated that the mice display obvious vis-
ceral pain behaviors on day 7 after injections of zymosan.
Quantification of Fos-immunoreactive (Fos-ir) neurons
showed that Fos was expressed at higher levels in many
areas of the forebrain, subcortex and brainstem of
zymosan-treated mice on day 7 than in the same brain
regions of saline-treated mice on day 7 (n = 6 slices from
6 mice per group; Figure 1). In forebrain areas, zymosan
treatment induced prominent Fos staining in layer II-III
of the ACC (zymosan: 186.4 ± 8.9; saline: 14.9 ± 2.5;
unpaired t-test, P < 0.001), the medial PFC (zymosan:
268.7 ± 11.4; saline: 59.6 ± 5.3; unpaired t-test, P < 0.001)
and layer II-III of the insular cortex (zymosan: 225.4 ±
12.3; saline: 45.2 ± 2.1; unpaired t-test, P < 0.001). In the
subcortex areas, Fos expression was mainly found in the
central nucleus of the amygdaloid complex (zymosan:
388.5 ± 10.6; saline: 33 ± 3.3; unpaired t-test, P < 0.001). In
the midbrain, zymosan treatment augmented Fos expres-
sion within the ventral posterolateral region of the peria-
queductal gray (PAG) (zymosan: 98.3 ± 5.2; saline: 9.5 ± 1.9;
unpaired t-test, P < 0.001). In the brainstem, abundant Fos
expression was also observed in the lateral region of the
parabrachial nucleus (PBN) (zymosan: 132.5 ± 6.6; saline:17.4 ± 1.1; unpaired t-test, P < 0.001) and in the medial and
commissural parts of the nucleus of solitary tract (NTS)
(zymosan: 87.9 ± 7.1; saline: 7.9 ± 1.0; unpaired t-test,
P < 0.001). These observations suggest that brain regions
associated with pain and emotion are activated in response
to intracolonic injection of zymosan.
Zymosan-induced visceral pain behaviors
We showed that brain regions related to pain and emo-
tional processing were activated in zymosan-induced
colitis, as shown by Fos immunohistochemical staining.
Next, we measured behavioral responses to confirm that
visceral pain was induced by intracolonic injection of zy-
mosan in adult mice [41,47,48]. As reported previously,
mouse postures defined as visceral pain-related behaviors
include licking of the abdomen in the absence of other
grooming behavior, whole-body stretching, flattening the
abdomen against the floor, or contracting the abdominal
wall such that an arched posture is adopted for 1–2 sec
(abdominal retractions) [49]. To evaluate the time course
of zymosan-induced visceral pain, 12 mice were divided
into zymosan- and saline-treated groups (n = 6 mice per
group). After intracolonic injections of zymosan or saline
for three consecutive days (Figure 2A), mice were then
tested for visceral pain behaviors on days 1, 7, 14 and 28
(Figure 2B). We found that zymosan-treated mice exhib-
ited obvious visceral pain-related behaviors on the first
day compared to saline-treated mice (zymosan: 27.7 ± 1.6;
vs. saline: 3.2 ± 1.1; P < 0.001; repeated measures ANOVA
followed by post hoc comparison with LSD test; Figure 2C).
Abdominal, visceral pain-related behaviors persisted for a
long period of time (zymosan: day 7: 25.3 ± 2.1; day 14:
26.8 ± 2.1; day 28: 26.0 ± 2.2; vs. saline: day 7: 3.5 ± 0.9; day
14: 3.7 ± 0.9; day 28: 3.3 ± 0.7; P < 0.001; repeated mea-
sures ANOVA followed by post hoc comparison with LSD
test; Figure 2B-C). In zymosan-treated mice, there were
no differences in the quantity of pain-related behaviors
within time points (F(3, 20) = 0.25, P = 0.86; one way
ANOVA; Figure 2C), suggesting that intracolonic injection
of zymosan can induce stable, chronic visceral pain. Thus,
our data indicate that intracolonic injection of zymosan
can induce obvious and persistent visceral pain behaviors
in mice.
Spontaneous pain increased in zymosan-treated mice
To further explore spontaneous pain of zymosan-treated
mice, we carried out experiments using the open field
test. To avoid habituation effects, independent groups
were used for each testing day. Thus, each mouse was
tested only once in the open field. In the open field test,
both spontaneous activities and travel distance were
measured automatically. Spontaneous activities include
vertical (rearing), ambulatory (horizontal activity), stereo-
typic (absence of locomotion but presence of repetitive,
Figure 1 The expression of Fos protein was upregulated
in different brain regions in zymosan-treated mice. (A)
Immunohistochemical staining for Fos in the ACC (anterior cingulate
cortex, 0.98 mm prior to bregma), PFC (prefrontal cortex, 1.78 mm
prior to bregma), IC (insular cortex, 1.18 mm prior to bregma), Amy
(amygdala, 1.46 mm posterior to bregma), PAG (periaqueductal gray,
4.72 mm posterior to bregma), PBN (parabrachial nucleus, 5.20 mm
posterior to bregma) and NTS (nucleus of solitary tract, 7.76 mm
posterior to bregma) at day 7 after intracolonic injection of zymosan
or saline (control). (CeA: central amygdala; cc: central canal; Scale
bar: ACC, PFC and IC, 250 μm; Amy and PAG, 150 μm; PBN and
NTS, 100 μm). (B) Histogram showing the quantification of
Fos-immunoreactive (Fos-ir) neurons in the above brain regions
of saline- and zymosan-treated mice (n = 6 slices per mouse;
6 mice per group). * denotes a significant difference between
zymosan- and saline-treated mice.
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and jump (escape latency) behaviors. Interestingly, counts
for all four of these behaviors were significantly decreased
in zymosan-treated mice on day 1 compared to saline-
treated groups. These decreases maintained on days 7, 14
and 28 (n = 6 mice per group for each testing day, two-
way ANOVA followed by post hoc comparison with
LSD test; Table 1, Figure 3A). There were no signifi-
cant differences among the day 1, 7, 14 and 28 groups
(Vertical: F(3, 40) = 2.57, P = 0.07; Ambulatory: F(3, 40) =
2.41, P = 0.08; Stereotypic: F(3, 40) = 2.21, P = 0.10; Jump:
F(3, 40) = 0.14, P = 0.94; two-way ANOVA followed byFigure 2 Behavioral tests of zymosan-treated mice. (A) A
volume of 0.1 ml zymosan (30 mg/ml) or saline was injected
transanally into the colons of mice via a needle connected to a PE
tube. (B) After injections on three consecutive days, behavioral tests
were administered to zymosan- and saline-treated mice on days 1, 7,
14 and 28 (n = 6 mice per group). (C) The number of pain behaviors
observed in zymosan-treated mice on days 1, 7, 14 and 28 increased
significantly compared to saline-treated mice (n = 6 mice per group).
* denotes a significant difference between zymosan- and saline-treated
mice. “Before” designated the mice before saline or zymosan
intracolonic treatment.
Table 1 Spontaneous activities counts of mice in the open field test
Counts Day Intracolonic saline Intracolonic zymosan P
Vertical 1 800.5 ± 63.8 492.2 ± 42.4 < 0.001
7 1055.3 ± 72.8 498.0 ± 51.8 < 0.001
14 976.7 ± 50.6 450.5 ± 53.2 < 0.001
28 1026.8 ± 58.6 438.2 ± 49.9 < 0.001
Ambulatory 1 1979.3 ± 158.2 1404.0 ± 133.3 < 0.05
7 2374.7 ± 155.7 1343.0 ± 152.5 < 0.001
14 2336.7 ± 172.2 1155.0 ± 117.4 < 0.001
28 2448.3 ± 161.9 1279.7 ± 147.4 < 0.001
Stereotypic 1 5011.3 ± 254.8, 4094.3 ± 257.1 < 0.05
7 4961.3 ± 260.0 3024.8 ± 214.6 < 0.001
14 5206.7 ± 265.7 3124.8 ± 289.2 < 0.001
28 4862.7 ± 259.3 2970.2 ± 218.7 < 0.001
Jump 1 120.8 ± 13.9 60.7 ± 10.6 < 0.01
7 129.5 ± 10.9 62.7 ± 9.7 < 0.001
14 122.5 ± 14.0 67.0 ± 8.5 < 0.01
28 117.8 ± 12.3 64.7 ± 11.5 < 0.01
P: in comparison with saline intracolonic treated group; n = 6 mice per group.
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As comparison, there were no significant differences
among saline-treated mice (n = 6 mice for each time
point) and naïve mice (n = 6 mice). An analysis of our
behavioral data with 5-min epochs showed that the
counts decreased consistently in zymosan-treated mice
within the 30-min testing time period compared to
saline-treated mice (Figure 3B).
In addition to four major behavioral counts, the total
travel distance of zymosan-treated mice in the open field
also markedly decreased days 1 (F(1, 40) = 4.83, P < 0.05),
7 (F(1, 40) = 10.56, P < 0.01), 14 (F(1, 40) = 15.75, P < 0.001)
and 28 (F(1, 40) = 17.97, P < 0.001) (n = 6 mice per group
for each testing day, two-way ANOVA followed by post
hoc comparison with LSD test; Figure 3D). The magni-
tude of reduction was similar among the day 1, 7, 14
and 28 groups (F(3, 40) = 0.83, P = 0.49; two-way ANOVA;
Figure 3D). These results consistently suggest that behav-
ioral changes in the open field test can be used to predict
the magnitude of spontaneous pain.
Zymosan-induced anxiety-like behaviors
Anxiety-like behavior in the open field is often assessed
by measuring exploratory behavior in the central field
within the first few minutes of beginning the open field
test [37,50]. Therefore, we analyzed the travel distance
within the central zone for zymosan-treated groups at
different time points, using a 5-min epoch. We found
that zymosan-treated mice travelled less distance within the
central area within the first 5 min of starting the test com-
pared to saline-treated mice (zymosan: day 1: 3.0 ± 0.9 m,P < 0.05; day 7: 2.5 ± 0.9 m, P < 0.05; day 14: 3.2 ± 0.8 m,
P < 0.05; day 28: 3.1 ± 0.8 m, P < 0.05; vs. saline: 6.9 ±
1.1 m; n = 6 mice per group for each testing day, two-way
ANOVA followed by post hoc comparison with Dunnett’s
test; Figure 3E). The magnitude of reduction was similar
among the day 1, 7, 14 and 28 groups (F(3, 20) = 0.06,
P = 0.98; two-way ANOVA; Figure 3E). We also found
that zymosan-treated mice spent less time in the central
area within the first 5 min of starting the test compared to
saline-treated mice (zymosan: day 1: 3.2 ± 0.6 s, P < 0.001;
day 7: 2.7 ± 0.5 s, P < 0.001; day 14: 3.5 ± 0.5 s, P < 0.001;
day 28: 3.1 ± 0.6 s, P < 0.001; vs. saline: 8.9 ± 0.9 s; n = 6
mice per group for each testing day, two-way ANOVA
followed by post hoc comparison with Dunnett’s test).
These findings indicate that zymosan-treated mice likely
experience more anxiety than saline-treated mice.
To further evaluate changes in anxiety-related behaviors,
we used the elevated plus maze and a light/dark box tests.
The elevated plus maze is based on an anxiogenic agent,
such as an unprotected elevated area, the anxiety level
being expressed by the number of entries into and the
length of time spent in the aversive area [51]. The light/
dark box is based on the innate aversion of rodents to
brightly illuminated areas and on the spontaneous explora-
tory behavior of rodents in response to stress or anxiety
[52]. Firstly, we found that the time spent in the open arms
of the elevated plus maze was significantly reduced in mice
in the day 1 group compared to saline-treated mice
(F(1, 40) = 22.63, P < 0.001; n = 6 mice per group for each
testing day, two-way ANOVA followed by post hoc com-
parison with LSD test; Figure 4A), suggesting that zymosan
Figure 3 (See legend on next page.)
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Figure 3 Behavioral assessment of zymosan-treated mice in the open field. (A) Counts of vertical, ambulatory, stereotypic and jump behaviors
in zymosan-treated mice were decreased compared to saline-injected mice on days 1, 7, 14 and 28 day (n = 6 mice per group for each testing day).
* denotes a significant difference between zymosan- and saline-treated mice. (B) Vertical, ambulatory, stereotypic and jump counts over 30 min on
days 1, 7, 14 and 28 for zymosan-treated mice (n = 6 for each testing day) and saline-treated mice (n = 24 mice). (C) Representative traces show the
movement of zymosan- and saline-treated mice in the open field test over a period of 30 min. (D) Zymosan-treated mice traveled significantly less
distance than did saline-treated mice on days 1, 7, 14 and 28 (n = 6 mice per group for each testing day). * denotes a significant difference between
zymosan- and saline-treated mice. (E) The distance traveled by zymosan-treated mice in the central zone within the first 5 min of the 30-min session
of the open field test was significantly reduced on days 1, 7, 14 and 28 (n = 6 mice for each testing day) compared to saline-treated mice (n = 24 mice).
* denotes a significant difference from saline-treated mice.
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the anxiety is long-lasting, we measured responses at
other time points. We found that zymosan-treated mice
spent less time in the open arms of the elevated plus
maze on days 7 (F(1, 40) = 47.09, P < 0.001), 14 (F(1, 40) =
35.12, P < 0.001) and 28 (F(1, 40) = 35.12, P < 0.001) (n = 6
mice per group for each testing day, two-way ANOVA
followed by post hoc comparison with LSD test; Figure 4A).
There was no difference among the day 1, 7, 14 and
28 groups (F(3, 40) = 0.74, P = 0.53; two-way ANOVA;
Figure 4A). The data suggest that zymosan-treated mice
exhibit long-term anxiety that lasted at least 4 weeks. By
contrast, there was no difference in the number of total
crossings between zymosan-treated mice and saline-
treated mice (F(1,40) = 1.36, P = 0.25; two-way ANOVA;
Figure 4B), indicating that the decreased activity of the
zymosan-treated mice in the open arms is not due to
hypoactivity.Figure 4 Behavioral assessment of anxiety in zymosan-treated mice.
behaviors in the elevated plus maze compared to saline-treated mice on day
significant difference between zymosan- and saline-treated mice. (B) No s
crossings (open + closed) of the elevated plus maze between zymosan- an
mice exhibited significant increases in anxiety-like behaviors in the light/d
(n = 6 mice per group for each testing day). * denotes a significant differe
significant difference between zymosan- and saline-treated mice was obs
the light/dark box test (P = 0.89).Finally, we examined behavioral responses in the light/
dark box test. We found that the time spent in the light
box was markedly decreased in mice in the day 1 group
compared to saline-treated mice (F(1, 40) = 6.03, P < 0.05;
n = 6 mice per group for each testing day, two-way
ANOVA followed by post hoc comparison with LSD test;
Figure 4C). We also examined mice at different time points
using the light/dark box to evaluate the time course of
zymosan-induced anxiety-like behaviors. Zymosan-treated
mice spent less time in the light box on days 7 (F(1, 40) =
15.83, P < 0.001), 14 (F(1, 40) = 12.44, P < 0.01) and 28
(F(1, 40) = 9.81, P < 0.01) (n = 6 mice per group for each
testing day, two-way ANOVA followed by post hoc
comparison with LSD test; Figure 4C). There were no
significant differences among the day 1, 7, 14 and 28 groups
(F(3, 40) = 0.42, P = 0.74; two-way ANOVA; Figure 4C). As
in the elevated plus maze, zymosan-treated mice also exhib-
ited anxiety-like behaviors in the light/dark box, and these(A) Zymosan-treated mice exhibited significant increases in anxiety-like
s 1, 7, 14 and 28 (n = 6 mice per group for each testing day). * denotes a
tatistically significant difference was observed in the numbers of total
d saline-treated mice on testing days (P = 0.25). (C) Zymosan-treated
ark box compared to saline-treated mice on days 1, 7, 14 and 28
nce between zymosan- and saline-treated mice. (D) No statistically
erved in the time until mice exited the dark box for the first time in
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cant differences in the time at which animals left the dark
box among these groups (F(1, 40) = 0.02, P = 0.89; two-way
ANOVA; Figure 4D), indicating that intracolonic injection
of zymosan does not influence the conflict between ro-
dents’ exploratory tendencies and aversive properties
of the environment.
NB001 and gabapentin alleviated zymosan-induced
visceral pain
Our previous studies indicated that AC1 contributes to
chronic pain–related neuronal plasticity in the brain and
the spinal cord [18,19,33,34,53,54]. Pharmacological in-
hibition of AC1 by NB001 has analgesic effects in animal
models of neuropathic pain and inflammatory pain [37].
However, the effect of NB001 on IBS has not been inves-
tigated. Gabapentin is a commonly used anticonvulsant
that also has analgesic effects on visceral hyperalgesia
[42-44,55,56]. Therefore, we decided to investigate the
effects of NB001 and gabapentin on visceral pain in
zymosan-treated mice. To avoid continuous effects and
interaction of drugs, independent groups were used for
all testing days. NB001 (3 mg/kg) or gabapentin (30 mg/kg)
was intraperitoneally (IP) injected into zymosan-treated
mice 45 min prior to behavioral testing.
We found that NB001 reduced visceral pain behaviors
in animals at 1 day after zymosan treatment (NB001:
21.0 ± 1.8, saline: 27.0 ± 2.0, P < 0.05; n = 6 mice per
group for each testing day, two-way ANOVA followed by
post hoc comparison with Dunnett’s test; Figure 5). The
inhibitory effects of NB001 were also observed at other
time points (day 7, NB001: 19.7 ± 2.4, saline: 26.7 ± 1.8,Figure 5 Effects of NB001 and gabapentin on visceral pain
behaviors in zymosan-treated and naïve mice. The histogram
shows that the number of visceral pain behaviors observed in
zymosan-treated mice on days 1, 7, 14 and 28 decreased significantly
after injection with NB001 (3 mg/kg, n = 6 mice) or gabapentin
(30 mg/kg, n = 6 mice) compared to mice injected with saline (n = 6
mice). * denotes a significant difference compared to saline-injected
mice. No significant difference was observed in the number of visceral
pain behaviors among naïve mice administered NB001, gabapentin or
saline (n = 6 mice per group; P = 0.87). Visceral pain was measured
45 min after IP injection.P < 0.01; day 14, NB001: 18.0 ± 1.6, saline: 26.5 ± 1.4,
P < 0.01; day 28, NB001: 19.0 ± 1.8, saline: 28.2 ± 1.8,
P < 0.001; n = 6 mice per group for each testing day,
two-way ANOVA followed by post hoc comparison with
Dunnett’s test; Figure 5). There were no significant differ-
ences among the effects of NB001 within each testing days
on zymosan-induced visceral pain (F(3, 20) = 0.43, P = 0.73;
one-way ANOVA; Figure 5). We also estimated the max-
imum possible inhibition (MPI) of NB001 (see Methods).
The mean MPI of NB001 on visceral pain behaviors was
about 30.5%.
We next examined the effects of gabapentin on visceral
pain in zymosan-treated mice. We found that gabapentin
injection also produced reduction in visceral pain behav-
iors (day 1: 19.8 ± 1.7, P < 0.01; day 7: 20.3 ± 1.4, P < 0.05;
day 14: 19.2 ± 1.7, P < 0.01; day 28: 20.0 ± 1.4, P < 0.01; in
comparison with saline injection group, n = 6 mice per
group for each testing day, two-way ANOVA followed by
post hoc comparison with Dunnett’s test; Figure 5). There
were no significant differences among the effects of
gabapentin within each testing days on zymosan-induced
visceral pain (F(3, 20) = 0.09, P = 0.96; one-way ANOVA;
Figure 5). The mean MPI of gabapentin on visceral pain
behaviors was 28.6%.
NB001 and gabapentin alleviated zymosan-induced
spontaneous pain
To evaluate further the effects of NB001 and gabapentin,
the open field test was used to measure spontaneous
pain. NB001 injection into zymosan-treated mice 45 min
prior to open field test increased spontaneous activities on
days 1, 7, 14 and 28 (n = 6 mice per group for each testing
day, two-way ANOVA followed by post hoc comparison
with Dunnett’s test; Table 2, Figure 6A). Interestingly,
NB001 produced more than 50% MPI on animal’s ambula-
tory counts, particularly on days 1 and 14 (day 1: 103.7%;
day 7: 81.6%; day 14: 94.7%; day 28: 79.9%). By contrast, the
mean MPIs of NB001 on the other spontaneous activities
counts were less than 40% (vertical: 30.3%; stereotypic:
39.2%; jump: 34.5%). Thus, the ambulatory counts may be
the most sensitive parameter to predict the analgesic ef-
fects of drugs on spontaneous visceral pain.
Injection of gabapentin in zymosan-treated mice also
increased spontaneous activities on days 1, 7, 14 and 28 in
comparison with saline injection group (n = 6 mice per
group for each testing day, two-way ANOVA followed
by post hoc comparison with Dunnett’s test; Table 2,
Figure 6A). Similar to NB001, gabapentin produced
more than 50% MPI on animal’s ambulatory counts,
especially on day 1 and 14 (day 1: 93.5%; day 7: 69.3%;
day 14: 90.4%; day 28: 86.4%). The mean MPIs of gaba-
pentin on the other spontaneous activities counts were
less than 40% (vertical: 31.3%; stereotypic: 36.9%; jump:
36.8%). The inhibitory effects produced by NB001 and
Table 2 Effects of NB001 or gabapentin IP injection on spontaneous activities counts of zymosan-treated mice
Counts Day Saline IP NB001 IP P Gabapentin IP P
Vertical 1 437.7 ± 44.4 612.3 ± 46.7 < 0.05 599.3 ± 50.4 < 0.05
7 437.3 ± 46.1 639.5 ± 44.8 < 0.01 646.2 ± 45.7 < 0.01
14 411.2 ± 46.6 600.2 ± 46.4 < 0.01 623.5 ± 51.8 < 0.01
28 400.3 ± 46.7 605.0 ± 43.9 < 0.01 621.0 ± 44.9 < 0.01
Ambulatory 1 1342.5 ± 197.6 2000.8 ± 199.2 < 0.05 1942.0 ± 193.9 < 0.05
7 1345.5 ± 224.19 2184.5 ± 214.7 < 0.01 2058.3 ± 205.0 < 0.05
14 1155.2 ± 211 2274.2 ± 208.5 < 0.001 2222.8 ± 212.1 < 0.001
28 985.3 ± 172.9 2210.8 ± 206.1 < 0.001 2289.8 ± 205.0 < 0.001
Stereotypic 1 3323.5 ± 252.9, 4214.0 ± 254.7 < 0.05 4418.0 ± 272.7 < 0.01
7 3039.7 ± 205.2 4038.2 ± 271.3 < 0.05 3944.3 ± 306.2 < 0.05
14 3103.7 ± 264.8 4002.7 ± 280.8 < 0.05 3885.7 ± 280.8 < 0.05
28 2895.2 ± 296.9 3904.0 ± 253.4 < 0.05 3920.2 ± 258.4 < 0.01
Jump 1 55.7 ± 5.3 79.0 ± 5.7 < 0.01 84.2 ± 7.2 < 0.01
7 60.3 ± 4.9 84.8 ± 4.7 < 0.01 82.0 ± 6.9 < 0.01
14 60.5 ± 5.61 82.2 ± 5.8 < 0.01 88.8 ± 5.2 < 0.01
28 63.8 ± 5.7 89.7 ± 5.4 < 0.01 85.8 ± 5.6 < 0.01
P: in comparison with saline IP injection group; n = 6 mice per group.
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P = 0.80; Ambulatory: P = 0.79; Stereotypic: P = 0.99; Jump:
P = 0.75; two-way ANOVA followed by post hoc compari-
son with LSD test; Table 2, Figure 6A).
In comparison with saline group, the decreased total
travel distance in zymosan-treated mice was also relieved
by either NB001 (day 1, P < 0.05; day 7, P < 0.05; day 14,
P < 0.01; day 28, P < 0.01; n = 6 mice per group for each
testing day, two-way ANOVA followed by post hoc com-
parison with Dunnett’s test; Figure 6B) or gabapentin
(day 1, P < 0.05; day 7, P < 0.05; day 14, P < 0.01; day 28,
P < 0.05; n = 6 mice per group for each testing day, two-
way ANOVA followed by post hoc comparison with
Dunnett’s test; Figure 6B). Both drugs produced more
than 50% MPI on total travel distance in zymosan-treated
mice, particularly on day 1 (day 1, NB001: 78.8%, gabapen-
tin: 83.5%; day 7, NB001: 60.4%, gabapentin: 51.6%; day
14, NB001: 59.5%, gabapentin: 56.3%; day 28, NB001:
59.2%, gabapentin: 61.7%).
Gabapentin but not NB001 reduced anxiety-like behaviors
in zymosan-treated mice
In the open field, injection of gabapentin (day 1, P < 0.01;
day 7, P < 0.01; day 14, P < 0.01; day 28, P < 0.01; in com-
parison with saline injection group, n = 6 mice per group
for each testing day, two-way ANOVA followed by post
hoc comparison with Dunnett’s test; Figure 6C), but not
NB001(day 1, P = 0.52; day 7, P = 0.42; day 14, P = 0.87;
day 28, P = 0.75; in comparison with saline injection
group, n = 6 mice per group for each testing day, two-way
ANOVA followed by post hoc comparison with Dunnett’stest; Figure 6C), increased the travel distance within the
central zone during the first 5 min of testing on all testing
days. We also found that injection of gabapentin (day
1, P < 0.01; day 7, P < 0.001; day 14, P < 0.001; day 28,
P < 0.001; in comparison with saline injection group, n = 6
mice per group for each testing day, two-way ANOVA
followed by post hoc comparison with Dunnett’s test), but
not NB001 (day 1, P = 0.37; day 7, P = 0.53; day 14, P =
0.61; day 28, P = 0.48; in comparison with saline injection
group, n = 6 mice per group for each testing day, two-way
ANOVA followed by post hoc comparison with Dunnett’s
test), increased the time spent in the central zone during
the first 5 min of testing on all testing days. Representative
traces showed that only gabapentin-injected mice were
more willing to explore the central zone (Figure 6D). The
mean MPI of gabapentin on the central zone travelling
was 96.6%, on the time spent in the central zone was
87.4%.
Mice injected with gabapentin spent more time in the
open arms of the elevated plus maze (day 1, P < 0.05; day
7, P < 0.001; day 14, P < 0.001; day 28, P < 0.001; in com-
parison with saline injection group, n = 6 mice per group
for each testing day, two-way ANOVA followed by post
hoc comparison with Dunnett’s test; Figure 7A). The
anti-anxiety effects of gabapentin in the elevated plus
maze were similar within each testing days (F(3, 20) = 1.23,
P = 0.33; one-way ANOVA; Figure 7A). The averaged MPI
of gabapentin on zymosan-treated mice in the elevated
plus maze was 28.4%. However, NB001 had no obvious ef-
fect on it (day 1, P = 0.73; day 7, P = 0.73; day 14, P = 0.99;
day 28, P = 0.61; in comparison with saline injection
Figure 6 Effects of NB001 and gabapentin on spontaneous pain and anxiety-like behaviors in the open field. (A) Counts of vertical,
ambulatory, stereotypic and jump behaviors in zymosan-treated mice on days 1, 7, 14 and 28 increased after injection of NB001 or gabapentin
compared to saline injection (n = 6 mice per group for each testing day). * denotes a significant difference compared to saline-injected mice.
(B) The distance traveled by zymosan-treated mice on days 1, 7, 14 and 28 increased after injection of NB001 or gabapentin compared to saline
injection (n = 6 mice per group for each testing day). * denotes a significant difference compared to saline-injected mice. (C) Gabapentin injection
significantly increased the distance traveled in the central zone within the first 5 min of the 30-min test session in zymosan-treated mice on days
1, 7, 14 and 28 compared to saline injection (n = 6 mice per group for each testing day). * denotes a significant difference compared to saline-injected
mice. No significant difference was observed between zymosan-treated mice injected with NB001 or saline on testing days (P= 0.63). (D) Representative
traces showed the movements of zymosan-treated mice injected with NB001, gabapentin or saline in the open field over a 30 min testing period on day
28. In each experiment, behavioral testing began 45 min after IP injection.
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ANOVA followed by post hoc comparison with Dunnett’s
test; Figure 7A). Neither drug influenced the total number
of crossings in the elevated plus maze at each time point
(F(3, 60) = 0.34, P = 0.80; two-way ANOVA; Figure 7B).
Finally, to further confirm the effect of gabapentin, we
performed experiments using the light/dark box. Mice
treated with gabapentin (day 1, P < 0.05; day 7, P < 0.05; day
14, P < 0.01; day 28, P < 0.05; in comparison with saline
injection group, n = 6 mice per group for each testing
day, two-way ANOVA followed by post hoc comparison
with Dunnett’s test; Figure 7C), but not NB001 (day 1,
P = 0.63; day 7, P = 0.85; day 14, P = 0.57; day 28, P = 0.89;in comparison with saline injection group, n = 6 mice per
group for each testing day, two-way ANOVA followed by
post hoc comparison with Dunnett’s test; Figure 7C), spent
more time in the light box. Neither drug influenced the
time at which animals left the dark box at each time point
(F(3, 60) = 0.71, P = 0.55; two-way ANOVA; Figure 7D),
indicating that neither NB001 nor gabapentin influences
the conflict between rodents’ exploratory tendencies and
aversive properties of the environment. Gabapentin pro-
duced more than 40% MPI on zymosan-treated mice in
the light/dark box, particularly on day 14 (day 1: 49.4%;
day 7: 45.4%; day 14: 59.2%; day 28: 40.5%). The data re-
veal that gabapentin alleviates anxiety-like behaviors via a
Figure 7 Effects of NB001 and gabapentin on zymosan-induced anxiety-like behaviors. (A) In the elevated plus maze, zymosan-treated
mice administered gabapentin exhibited a significant reduction in anxiety-like behaviors on days 1, 7, 14 and 28 compared to mice administered
saline (n = 6 mice per group for each testing day). * denotes a significant difference compared to saline-injected mice). No statistically significant
difference was observed between zymosan-treated mice administered NB001 or saline on testing days (P = 0.43). (B) No statistically significant
difference was observed in the total number of crossings (open + closed) in the elevated plus maze among zymosan-treated mice administered
saline, gabapentin or NB001 on testing days (P = 0.80). (C) In the light/dark box test, zymosan-treated mice administered gabapentin exhibited a
significant reduction in anxiety-like behaviors on days 1, 7, 14 and 28 compared to saline-injected mice (n = 6 mice per group for each testing
day). * denotes a significant difference compared to saline-injected mice). There was no significant difference between zymosan-treated mice
administered NB001 (n = 6 mice) or saline on testing days (P = 0.97). (D) No statistically significant difference was observed in the time until
animals leave the dark box in the light/dark box test among zymosan-treated mice administered either saline, gabapentin or NB001 on testing
days (P = 0.55). In each experiment, behaviors were measured 45 min after IP injection.
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is unable to alleviate zymosan-induced anxiety-like behav-
iors in mice.
Discussion
In the present study, we examined the neurobehavioral
manifestations of zymosan-induced colitis in mice and
the effects of NB001 and gabapentin on mice treated
with zymosan. Our results included three novel findings:
(1) Elevated expression of Fos protein in the brains of
zymosan-treated mice demonstrated that cortical areas
are involved in the regulation of pain and emotions in
mice experiencing zymosan-induced colitis. (2) Zymosan-
treated mice exhibited obvious, spontaneous visceral pain
and anxiety-like behaviors, which persisted for at least
4 weeks after treatment. (3) An investigation of the effects
of NB001 and gabapentin on zymosan-induced colitis
showed that both drugs had markedly antinociceptive
effects. Furthermore, gabapentin, but not NB001, was able
to alleviate anxiety in zymosan-treated mice.
Fos protein was expressed at high levels in the brain
after the induction of colitis with zymosan
Analysis of serial coronal sections showed elevated levels
of Fos protein in the PFC, ACC, insular cortex, amygdala,
PAG, PBN and nucleus of solitary tract in zymosan-
treated mice. Among these brain regions, the PFC, ACC,insular cortex, amygdala and PAG are involved in the pro-
cessing of pain information and emotional responses [18],
the lateral region of PBN is involved in the processing of
general visceral inputs [57], and the medial and commis-
sural parts of the nucleus of solitary tract are the primary
targets for afferent vagal fibers [58]. Our observations
demonstrate that zymosan-induced colitis causes obvious
nociception in mice. The elevated levels of Fos protein in
some brain areas related to emotional processing suggests
that mice may suffer from emotional disorders following
the induction of colitis with zymosan.
Intracolonic injection of zymosan induced chronic
visceral pain
Previous work showed that intracolonic treatment with
zymosan could produce a model of chronic colon hyper-
sensitivity involving a transient low-level inflammation
[40,41,47]. Thus, zymosan is capable of producing visceral
hypersensitivity in rodents. Zymosan induced visceral pain
is a suitable model to study potential mechanisms
underlying visceral hypersensitivity, including human
IBS, because of its lack of associated colon pathology.
In the present study, typical chronic visceral pain be-
haviors, such as licking of the abdomen in the absence
of other grooming behavior, whole-body stretching,
flattening the abdomen against the floor and contracting
the abdominal wall, were observed in zymosan-treated
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long-lasting reductions in ambulatory, vertical, stereotypic
and jump counts, as well as travel distance, in zymosan-
treated mice when tested in the open field. These findings
suggest that the abdominal visceral pain caused by zymo-
san influences the spontaneous responses and action
intention of mice. A similar phenomenon of reduced ac-
tivity occurs in people suffering from IBS, as well [59,60].
Thus, spontaneous visceral pain induced by intracolonic
injection of zymosan could be measured via decreased
spontaneous activity in the open field. Moreover, measure-
ment of spontaneous activities in the open field test could
be used to predict the ability of experimental IBS therapies
to reduce spontaneous visceral pain.Zymosan-treated mice exhibited persistent anxiety-like
behaviors
There is a high rate of co-morbidity between IBS and
psychological disorders such as anxiety, stress and depres-
sion [11-15]. We demonstrated that zymosan-treated mice
experienced more anxiety compared to saline-treated
mice, as measured by the distance traveled and time spent
in the central zone in the open field test and using the
elevated plus maze and the light/dark box tests. Thus,
visceral noxious stimulation is interpreted to cause in-
teroceptive anxiety in zymosan-treated mice. Previous
human and animal studies also showed that anxiety-like
behaviors could be induced by inflammatory pain, chronic
musculoskeletal pain or neuropathic pain [61-67]; but see
[68]. In addition, recent research suggests that dysbiosis of
the gut microbiota is implicated in the pathogenesis of
IBS [69]. Commensal bacteria are known to affect a variety
of complex behaviors, including social, emotional, and
anxiety-like behaviors, and contribute to brain develop-
ment and function in mice and human [70,71]. Thus,
intracolonic treatment with zymosan may cause intestinal
dysbiosis and lead to anxiety.Effects of NB001 on zymosan-treated mice
AC1 is activated by calcium-calmodulin- (CaM-) dependent
manner. It acts downstream from glutamate NMDA re-
ceptors and contributes to chronic pain-related neuronal
plasticity in the cortex and spinal cord [18,19,33,34,53,54].
In the present study, NB001, an AC1 inhibitor, exerted ob-
vious antinociceptive effects on visceral pain induced by
intracolonic injection of zymosan. Because NB001 has no
effect on motor function in normal mice [37], we specu-
late that NB001 increases the spontaneous behaviors of
zymosan-treated mice by attenuating spontaneous visceral
pain. Our data suggest that the AC1 signaling pathway
plays an important role in the processing of visceral pain
induced by intracolonic injection of zymosan. According
to the MPI, the ambulatory counts may be the mostsensitive parameter to predict the analgesic effects of
drugs on spontaneous visceral pain.
NB001 did not dampen anxiety-like behaviors in
zymosan-treated mice, consistent with our previous
finding that NB001 had no effect on anxiety-like behaviors
in normal mice [37]. We believe that pain causes cortical
plasticity and that brains likely exhibit ‘metaplasticity’ in
response to continuous inputs from the periphery [18,72].
Thus, persistent, noxious visceral stimuli in the present
study were able to cause a long-lasting pain-related emo-
tional disorder, in this case anxiety. In addition, although
pain-related anxiety is coupled to pain, growing evidence
indicates that pain-related anxiety is dissociated from
pain perception [73]; this finding provides an explanation
for our observations that NB001 is unable to alleviate
zymosan-induced anxiety by attenuating visceral pain in
mice and that gabapentin can reduce anxious behaviors by
a mechanism unrelated to antinociception. More research
is needed to find additional methods for attenuating pain-
induced anxiety.
Effects of gabapentin on zymosan-treated mice
Gabapentin interacts with a subunit of voltage-sensitive
calcium (Ca2+) channels [74] and modulates the function
of peripheral and central pain pathways by influencing
fast synaptic transmission and neuronal excitability [75,76].
Consistent with previous work, our data suggest that
gabapentin relieves chronic visceral pain induced by
intracolonic injection of zymosan and reduces spon-
taneous pain through a multiplicity of mechanisms. In
addition, gabapentin has also been associated with a
reversal of anxiety-like behaviors in animal models of
neuropathic pain [77,78]. The present results indicated
that gabapentin significantly decreases anxiety-like be-
haviors in zymosan-treated mice, which is coincident
with its anti-nociceptive effect. Our observation that
gabapentin reduces anxiety-like behaviors in zymosan-
treated mice provides evidence to support the potential
use of gabapentin for the treatment of IBS-related emo-
tional disorders. However, the side effects of gabapentin,
including hepatotoxicity and neurologic toxicities [79-81],
should be taken into account if this drug is considered for
the symptomatic treatment of IBS.
For the first time, we have presented evidence that
changes in spontaneous behavioral responses are a reflec-
tion of spontaneous pain induced by intracolonic injection
of zymosan. Mice with zymosan-induced colitis exhibited
significant increases in anxiety-like behaviors. We first
demonstrated that the expression of Fos protein is not-
ably increased in several brain areas, and particularly in
regions involved in the processing of pain and emotions;
this finding suggests that these cortical and subcortical
areas are involved in the response to zymosan-induced
colitis. From the point of view of translational medicine,
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visceral pain induced by intracolonic injection of zymosan
but had no effect on anxiety, whereas IP injection of
gabapentin alleviated both spontaneous visceral pain
and anxiety in zymosan-treated mice. Our findings
provide a basis for these drugs to be considered for the
clinical pharmacological treatment of IBS.
Methods
Animals
Experiments were performed with adult (age 8–12 weeks)
male C57/BL6 mice purchased from Charles River La-
boratories (St. Constant, Quebec, Canada). Animals were
housed under standard laboratory conditions (12 h light/
12 h dark, temperature 22-26°C, humidity 55-60%) with
water and mice chow available ad libitum. All experiments
were performed in accordance with protocols approved by
the Animal Care Committee of the University of Toronto
and Animal Care and Use Committee of the Fourth
Military Medical University.
Zymosan-induced colitis in animals
Colitis was induced in animals by the administration of
zymosan, as described previously [41,47,48]. Mice were
anesthetized by isoflurane inhalation (1-3%, or as needed).
During surgery, body temperature was maintained at 37°C
using a heating pad. A lubricant ointment (artificial tears)
was applied to the eyes. A volume of 0.1 ml zymosan sus-
pension (30 mg/ml in saline; derived from Saccharomyces
cerevisiae; Sigma, St. Louis, MO) was administered trans-
anally via a 22-gauge, 24-mm-long stainless-steel feeding
needle into the colons of mice over a period of 2 min. A
control group of mice was subjected to a similar proced-
ure except that 0.1 ml saline was administered transanally.
Zymosan or saline were given daily for three consecutive
days.
Immunohistochemical staining
On day 7, zymosan-treated mice and saline-treated mice
were deeply anesthetized and perfused with 50 ml of
0.9% saline, followed by 100 ml of 0.1 M PB containing
4% (w/v) paraformaldehyde. Immediately after perfusion,
brains were removed and placed into 0.1 M PB containing
30% (w/v) sucrose overnight at 4°C and cut into 25 μm-
thick serial frontal sections on a freezing microtome
(Kryostat 1720; Leitz, Mannheim, Germany). The sections
were collected in sequence, divided into 2 series and
washed with 0.01 M phosphate buffer solution (PBS,
pH 7.4). The sections were incubated with mouse anti-Fos
antiserum (1:500; Abcam, Cambridge, MA, USA) in PBS
containing 5% (v/v) normal donkey serum (NDS), 0.3%
(v/v) Triton X-100, 0.05% (w/v) NaN3 and 0.25% (w/v)
carrageenan (PBS-NDS, pH 7.4) overnight at 4°C.Next, the sections were washed and then incubated with
biotinylated anti-mouse IgG (1:200, Millipore Corpor-
ation, USA) for 2 h at room temperature (approximately
22°C). Sections were then washed (3 × 10 min) in PBS and
incubated in avidin-biotin complex (ABC kit, Vector
Laboratories, Inc., USA) for 30 min. After incubation in
avidin-biotin complex, sections were washed (3 × 10 min)
again and reacted with 0.05 M of Tris–HCl buffer (pH 7.6)
containing 0.04% diaminobenzidinetetrahydrochloride
(DAB) (Dojin, Kumamoto, Japan) and 0.003% H2O2 for
visualizing Fos; Fos-positive nuclei appear dark brown.
Sections were washed again (once immediately after
removing the DAB solution, then 3 × 10 min), then
mounted on gelatin-coated glass slides, and allowed to
air dry overnight. Sections were dehydrated in increasing
concentrations of ethanol, cleared, and coverslipped
for examination by light microscopy (AHBT3; Olympus,
Tokyo, Japan).
Quantification of Fos expression
The counts of Fos-ir neurons in the brain regions were
represented as the average number of neurons per sec-
tion. We limited our analysis to the PFC, ACC, insular
cortex, amygdala, PAG, NTS, and PBN because most
immunolabeled neurons in the brains of zymosan-treated
mice were in these regions. The numbers of labeled
neurons in a given brain region were estimated from
the counts of positively stained cells in a minimum of 6
sections per brain region. To avoid counting a neuron
more than once, sections used for the counts were sepa-
rated by at least 100 μm. The differences in cell counts
were evaluated statistically by unpaired t-test to examine
the interactions among groups. Counting was per-
formed by an investigator who was blind to the treatment
condition.
Behavioral testing
Counts of visceral pain behaviors: Visceral pain behaviors,
as described by Laird [49], included licking of the abdo-
men in the absence of other grooming behavior, whole-
body stretching, flattening the abdomen against the floor,
or contracting the abdominal wall such that an arched
posture was adopted for 1–2 sec (abdominal retractions).
The total number of visceral pain behaviors was recorded
over a period of 10 min.
Open field: Mice were placed in a novel open field
(43.2 × 43.2 × 30.5 cm3; Med Associates, St. Albans,
Vermont) inside a dimly lit isolation chamber (<50 lux
in the center of the open field) with a fan. An activity
monitoring system (Activity Monitor, Med Associates,
St. Albans, Vermont) was used to record horizontal
locomotor activity. Briefly, this system uses paired sets
of photo beams to detect movement (number of photo
beams: 16; space between the beams: 2.5 cm; number
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center of the open field, and activity was measured for
30 min. Central zone was defined by zones from (4, 4)
to (13, 13).
Elevated plus maze: The elevated plus maze (Med
Associates, St. Albans, Vermont) consisted of two open
arms in line with each other placed perpendicularly to
two closed arms in line with each other [82]. The maze
was situated 70 cm from the floor. For each test, individ-
ual animals were placed in the center square with the head
facing a closed arm. The number of entries into and time
spent in each arm were recorded for 5 min.
Light/dark box: The light/dark box used in this study
was a modified version of a light/dark box described
previously by Kim et al. [23]. The apparatus consisted of
a rectangular Plexiglas box (44 × 8.5 × 25 cm3) divided
into equal-size light and dark compartments separated
by a door. The light box was lit by a 60-W desk lamp
(400 lux) placed 30 cm above the box. Each animal was
placed in the dark compartment and was allowed 20 section
to explore, after which the door to the light compartment
was opened. The time until the animal left the dark box
and the time spent in the light box were recorded for
10 min.
Mice were acclimatized to the observation room for
30 min prior to behavioral tests. The behavioral tests
were performed by an investigator who was blind to the
treatment condition from 9:00 am to 12:00 pm.
Drugs injection
Mice were administered NB001 3 mg/kg or gabapentin
(Tocris Bioscience) 30 mg/kg IP prior to behavioral tests.
Statistical analysis
All data were collected by experimenters who were
blind to the surgical and chemical treatments. Statistical
analysis was performed using SPSS software (version
21). Data were expressed as the mean ± standard error
of the mean (mean ± S.E.M.). Inhibition of visceral pain
or anxiety was presented as maximum possible inhib-
ition (MPI) = (Pdrug - Pzymosan)/(Psaline - Pzymosan) × 100%
(Pdrug: value of parameter detected in each behavior test in
zymosan-treated mice with NB001 or gabapentin IP injec-
tion; Pzymosan: value of parameter detected in each behav-
ior test in mice with zymosan intracolonic treatment;
Psaline: value of parameter detected in each behavior test
in mice with saline intracolonic treatment). When ne-
cessary, statistical significance was assessed by un-
paired t-test, repeated measures ANOVA followed by
post hoc comparison with LSD test, one way ANOVA,
two-way ANOVA followed by post hoc comparison
with LSD test or two-way ANOVA followed by post hoc
comparison with Dunnett’s test. A threshold for statistical
significance of P < 0.05 was chosen.Abbreviations
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